恩替卡韦联合聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎的临床研究

摘要

Objective To explore in the clinical treatment of HBeAg positive chronic hepatitis B by grace for entecavir plus pegylated interferon alpha-2a treatment to observe the clinical curative effect.Methods From June 2014 to September 2015 in hospital to accept the diagnosis and treatment of 80 cases of HBeAg positive chronic hepatitis B patients divided into study group and control group, each with 40 cases in each, two groups of patients are implemented the same general liver protective treatment, on this basis, control group were given simple entecavir card Wei treatment, the patients in the study group by grace for entecavir plus pegylated interferon alpha-2a treatment, compared two groups of patient outcomes.ResultsThe effective rate of patients in the study group was signiifcantly higher than that in the control group, there were signiifcant differences, with statistical signiifcance (P<0.05).Conclusion In the treatment of HBeAg positive chronic hepatitis B by grace for entecavir plus pegylated interferon alpha-2a treatment, has good clinical efifcacy.%目的：探究在HBeAg阳性慢性乙型肝炎的临床治疗中，采用恩替卡韦联合聚乙二醇干扰素α-2a进行治疗，观察其临床疗效。方法选取2014年6月~2015年9月来本院接受诊治的80例HBeAg阳性慢性乙型肝炎患者分成研究组和对照组，每组40例，两组患者都实施同样的一般保肝治疗，在此基础上，对照组患者给予单纯的恩替卡韦治疗，研究组患者采用恩替卡韦联合聚乙二醇干扰素α-2a进行治疗，比较两组患者疗效。结果研究组患者治疗有效率明显高于较对照组，存在显著性差异，具有统计学意义（P＜0.05）。结论在HBeAg阳性慢性乙型肝炎的临床治疗中，采用恩替卡韦联合聚乙二醇干扰素α-2a进行治疗，具有良好的临床疗效。